GlassScriptPhysician profile
Peter W Wu
NPI 1639469828
$5,866.62
in general payments reported to CMS, 2019-2025
21 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $73.67 · 2021: $284 · 2022: $646 · 2023: $1,602 · 2024: $1,966 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,835.27 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,676.78 | 2022-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Janssen Pharmaceuticals, INC | $401.63 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $310.43 | 2023-2025 | Acthar |
| Glaukos Corporation | $264.12 | 2022-2024 | Ce-Marked Kxla System |
| Rxsight INC | $246.96 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Genentech USA, INC. | $245.13 | 2023-2024 | Vabysmo |
| Abbvie INC. | $228.96 | 2022-2025 | Lumigan, Alphagan P |
| Apellis Pharmaceuticals, INC. | $224.68 | 2023-2024 | Syfovre |
| Novo Nordisk INC | $204.19 | 2022-2025 | Ozempic, Rybelsus |
| Biotissue Holdings INC. | $193.79 | 2024-2025 | |
| Dompe US, INC. | $193.60 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $173.61 | 2023-2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $87.67 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Bausch & Lomb Americas INC. | $78.03 | 2024-2025 | Scoutpro Osmolarity System, Envista Mx60 Iol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $61.13 | 2024 | |
| Horizon Therapeutics Plc | $41.61 | 2023 | Tepezza |
| Harrow Eye, LLC | $38.04 | 2024-2025 | Iheezo |
| Tarsus Pharmaceuticals, INC. | $33.65 | 2024-2025 | Xdemvy |
| Amgen INC. | $20.44 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $20.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.